An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function-Reference-Cited by-同舟云学术

An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function

Published:2018-11 Issue: Volume:74 Page:68-74
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Maimaitili Yimamu,Inase Aki,Miyata Yoshiharu,Kitao Akihito,Mizutani Yu,Kakiuchi Seiji,Shimono Yohei,Saito Yasuyuki,Sonoki Takashi,Minami Hironobu,Matsuoka Hiroshi

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference40 articles.

1. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia;Ehninger;Blood Cancer J.,2014

2. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors;Tettamanti;Immunol. Lett.,2013

3. Expression of normal myeloid-associated antigens by acute leukemia cells;Dinndorf;Blood,1986

4. Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis;Schwonzen;Leuk. Res.,2007

5. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy;Walter;Blood,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07

2. Genomic profile of Parkinson's disease in Asians;Clinica Chimica Acta;2024-01

3. GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance;eJHaem;2022-12-12

4. Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond;Vaccines;2021-09-29

5. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin;Cancers;2021-09-11